تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
18.15 US$
+0.24 US$ · +1.34%
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
الإغلاق السابق
18.15 US$
+0.24 US$ · +1.34%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
نطاق اليوم
السعر الحالي 18.15 US$
نطاق 52 أسبوعًا
السعر الحالي 18.15 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
نطاق اليوم
السعر الحالي 18.15 US$
نطاق 52 أسبوعًا
السعر الحالي 18.15 US$
| البند (USD) | السنة المالية 2025 |
|---|---|
| البحث والتطوير | 66.31 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 20.98 مليون USD |
| نفقات التشغيل | 87.29 مليون USD |
| دخل الفوائد | 11.4 مليون USD |
| الاستهلاك والإطفاء | 1.41 مليون USD |
| الدخل التشغيلي | −87.29 مليون USD |
| صافي الدخل | −74.88 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI10.1 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
iShares Russell 2000 ETFIWM6.47 مليون0.01%78.74 مليار USD0.19%278.94 US$+0.49%
Vanguard Extended Market ETFVXF3.97 مليون0.00%95.4 مليار USD0.05%235 US$+0.80%
AdvisorShares Psychedelics ETFPSIL1.59 مليون3.38%46.85 مليون USD1.84%21.765 US$+3.69%
Schwab U.S. Small-Cap ETFSCHA1.39 مليون0.01%21.82 مليار USD0.03%32.79 US$+0.40%
iShares Russell 2000 Growth ETFIWO1.38 مليون0.01%13.92 مليار USD0.24%356.78 US$+0.94%
ALPS Medical Breakthroughs ETFSBIO1.23 مليون0.64%191.36 مليون USD0.50%55.04 US$+2.03%
iShares Micro-Cap ETFIWC803.25 ألف0.06%1.32 مليار USD0.60%183 US$+0.11%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFAdvisorShares Psychedelics ETFPSILSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOALPS Medical Breakthroughs ETFSBIOiShares Micro-Cap ETFIWCالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.